To demonstrate that upregulation of EPHA2 and MET also occurs in tumors of patients who develop resistance to BRAFi therapy we have analyzed tumor samples obtained before treatment and after progression in three melanoma patients receiving treatment with BRAFi. The gene discussed is EPHA2; the disease is melanoma.